Moreover, in publicly available clinical tumor expression data sets, we noted that FOXD3 was down-regulated in colon cancer and cervix cancer, while was up-regulated in renal cancer and endometrial cancer. This evidence concerns the gene FOXD3 and renal carcinoma.